A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies (MDX1106-01)

Clinical Trial ID NCT00441337

PubWeight™ 28.85‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00441337

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010 17.13
2 Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 2014 1.59
3 B7 family checkpoint regulators in immune regulation and disease. Trends Immunol 2013 1.53
4 Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett 2009 1.04
5 Tumor evasion from T cell surveillance. J Biomed Biotechnol 2011 1.01
6 Role of immunotherapy for renal cell cancer in 2011. J Natl Compr Canc Netw 2011 0.91
7 Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci 2013 0.88
8 Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer. Cancer J 2014 0.88
9 Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res 2014 0.87
10 PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. Onco Targets Ther 2014 0.85
11 Evolving Concepts: Immunity in Oncology from Targets to Treatments. J Oncol 2015 0.81
12 PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother 2014 0.80
13 Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy. J Clin Immunol 2011 0.78
14 Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015. J Transl Med 2016 0.77
15 Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma. ESMO Open 2016 0.77
Next 100